Multidisciplinary Cancer Investigation
Wed, Oct 7, 2026
[Archive]
Volume 0 - Multidisciplinary Cancer Investigation
Multidiscip Cancer Investig 2025, 0 - Multidisciplinary Cancer Investigation: 31-46 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Sheikhi Z, Vafakhah M, Mirzaei H, Khosravi M, Gilany K. Oncometabolites: The Metabolic Shadow of Oncogenes. Multidiscip Cancer Investig 2025;
URL: http://mcijournal.com/article-1-419-en.html
URL: http://mcijournal.com/article-1-419-en.html
1- Integrative Oncology Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran
2- Reproductive Biotechnology Research Center, Avicenna Research Institute, ACECR, Tehran, Iran
3- Integrative Oncology Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran & Reproductive Biotechnology Research Center, Avicenna Research Institute, ACECR, Tehran, Iran ,k.gilany@avicenna.ac.ir
2- Reproductive Biotechnology Research Center, Avicenna Research Institute, ACECR, Tehran, Iran
3- Integrative Oncology Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran & Reproductive Biotechnology Research Center, Avicenna Research Institute, ACECR, Tehran, Iran ,
Abstract: (871 Views)
Oncometabolites such as L-lactate, succinate, fumarate, R-2-hydroxyglutarate, kynurenine, and itaconate are emerging as pivotal drivers of cancer progression. Beyond their metabolic roles, these molecules function as signaling mediators that remodel epigenetic landscapes, reprogram the tumor microenvironment, and promote immune evasion. This review synthesizes current insights into their biochemical origins, oncogenic mechanisms, and therapeutic potential, highlighting how targeting oncometabolite-driven pathways could facilitate the development of novel cancer therapies.
Keywords: Fumarate , Iltaconate , Kynurenine , L-lactate , Oncometabolites , R-2-Hydroxyglutarate , Succinate
Select article type: Review Article |
Subject:
Molecular Mechanisms
Received: 2024/09/4 | Accepted: 2024/12/13 | ePublished: 2025/09/22
Received: 2024/09/4 | Accepted: 2024/12/13 | ePublished: 2025/09/22
References
1. Gilany K, Vafakhah M. Hypoxia: a review. Arch Adv Biosci. 2010;1(2). doi:10.22037/jps.v1i2.1616
2. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324(5930):1029-1033. [DOI:10.1126/science.1160809] [PMID]
3. Ward PS, Thompson CB. Metabolic reprogramming: a cancer hallmark even Warburg did not anticipate. Cancer Cell. 2012;21(3):297-308. [DOI:10.1016/j.ccr.2012.02.014] [PMID]
4. Ben-Haim S, Ell P. 18F-FDG PET and PET/CT in the evaluation of cancer treatment response. J Nucl Med. 2009;50(1):88-99. [DOI:10.2967/jnumed.108.054205] [PMID]
5. Buck AC, Schirrmeister HH, Guhlmann CA, Diederichs CG, Shen C, Buchmann I, et al. Ki-67 immunostaining in pancreatic cancer and chronic active pancreatitis. J Nucl Med. 2001;42(5):721-725.
6. Anastasiou D, Poulogiannis G, Asara JM, Boxer MB, Jiang JK, Shen M, et al. Inhibition of pyruvate kinase M2 by reactive oxygen species. Science. 2011;334(6060):1278-1283. [DOI:10.1126/science.1211485] [PMID] [PMCID]
7. Pollard PJ, Brière JJ, Alam NA, Barwell J, Barclay E, Wortham NC, et al. Accumulation of Krebs cycle intermediates in FH and SDH mutant tumors. Hum Mol Genet. 2005;14(15):2231-2239. [DOI:10.1093/hmg/ddi227] [PMID] [PMCID]
8. Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009;462(7274):739-744. [DOI:10.1038/nature08617] [PMID] [PMCID]
9. Ward PS, Patel J, Wise DR, Abdel-Wahab O, Bennett BD, Coller HA, et al. Neomorphic enzyme activity of mutant IDH1 and IDH2. Cancer Cell. 2010;17(3):225-234. [DOI:10.1016/j.ccr.2010.01.020] [PMID]
10. DeBerardinis RJ, Thompson CB. Cellular metabolism and disease. Cell. 2012;148(6):1132-1144. [DOI:10.1016/j.cell.2012.02.032] [PMID]
11. Kaelin WG Jr. Cancer and altered metabolism. Cold Spring Harb Symp Quant Biol. 2011;76:1-7. [DOI:10.1101/sqb.2011.76.010975] [PMID] [PMCID]
12. Thompson CB. Metabolic enzymes as oncogenes or tumor suppressors. N Engl J Med. 2009;360(8):813-815. [DOI:10.1056/NEJMe0810213] [PMID] [PMCID]
13. Yang M, Soga T, Pollard PJ, Adam J. The emerging role of fumarate as an oncometabolite. Front Oncol. 2012;2:85. [DOI:10.3389/fonc.2012.00085]
14. Zhang Z, Tan M, Xie Z, Dai L, Chen Y, Zhao Y. Lysine succinylation as a new post-translational modification. Nat Chem Biol. 2011;7(1):58-63. [DOI:10.1038/nchembio.495] [PMID] [PMCID]
15. Missiroli S, Perrone M, Genovese I, Pinton P, Giorgi C. Cancer metabolism and mitochondria. EBioMedicine. 2020;59:102943. [DOI:10.1016/j.ebiom.2020.102943] [PMID] [PMCID]
16. Warburg O. On the origin of cancer cells. Science. 1956;123(3191):309-314. [DOI:10.1126/science.123.3191.309] [PMID]
17. DeBerardinis RJ, Chandel NS. We need to talk about the Warburg effect. Nat Metab. 2020;2(2):127-129. [DOI:10.1038/s42255-020-0172-2] [PMID]
18. Fendt SM. 100 years of the Warburg effect. Cell. 2024;187(15):3824-3828. [DOI:10.1016/j.cell.2024.06.026] [PMID]
19. Kim J, DeBerardinis RJ. Metabolic heterogeneity in cancer. Cell Metab. 2019;30(3):434-446. [DOI:10.1016/j.cmet.2019.08.013] [PMID] [PMCID]
20. Ju YS, Alexandrov LB, Gerstung M, Martincorena I, Nik-Zainal S, Ramakrishna M, et al. Mitochondrial DNA mutations in cancer. eLife. 2014;3:e02935. [DOI:10.7554/eLife.02935] [PMID] [PMCID]
21. Chen YJ, Mahieu NG, Huang X, Singh M, Crawford PA, Johnson SL, et al. Lactate metabolism and mitochondria. Nat Chem Biol. 2016;12(11):937-943. [DOI:10.1038/nchembio.2172] [PMID] [PMCID]
22. Sonveaux P, Végran F, Schroeder T, Wergin MC, Verrax J, Rabbani ZN, et al. Targeting lactate-fueled respiration. J Clin Invest. 2008;118(12):3930-3942. [DOI:10.1172/JCI36843] [PMID] [PMCID]
23. DeBerardinis RJ, Chandel NS. Fundamentals of cancer metabolism. Sci Adv. 2016;2(5):e1600200. [DOI:10.1126/sciadv.1600200] [PMID]
24. Faubert B, Solmonson A, DeBerardinis RJ. Metabolic reprogramming and cancer progression. Science. 2020;368(6487):eaaw5473. [DOI:10.1126/science.aaw5473] [PMID]
25. Kold-Christensen R, Johannsen M. Methylglyoxal metabolism and aging-related disease. Trends Endocrinol Metab. 2020;31(2):81-92. [DOI:10.1016/j.tem.2019.10.003] [PMID]
26. Baumann T, Dunkel A, Schmid C, Schmitt S, Hiltensperger M, Lohr K, et al. Methylglyoxal-mediated T cell paralysis. Nat Immunol. 2020;21(5):555-566. [DOI:10.1038/s41590-020-0666-9] [PMID]
27. Astuti D, Latif F, Dallol A, Dahia PL, Douglas F, George E, et al. SDHB mutations and pheochromocytoma. Am J Hum Genet. 2001;69(1):49-54. [DOI:10.1086/321282] [PMID] [PMCID]
28. Baysal BE, Ferrell RE, Willett-Brozick JE, Lawrence EC, Myssiorek D, Bosch A, et al. SDHD mutations in paraganglioma. Science. 2000;287(5454):848-851. [DOI:10.1126/science.287.5454.848] [PMID]
29. Lancaster CRD. Succinate:quinone oxidoreductases. Biochim Biophys Acta. 2002;1553(1-2):1-6. [DOI:10.1016/S0005-2728(01)00240-7]
30. Van Vranken JG, Na U, Winge DR, Rutter J. Assembly of succinate dehydrogenase. Crit Rev Biochem Mol Biol. 2015;50(2):168-180. [DOI:10.3109/10409238.2014.990556] [PMID] [PMCID]
31. Pasini B, Stratakis CA. SDH mutations in tumorigenesis. J Intern Med. 2009;266(1):19-42. [DOI:10.1111/j.1365-2796.2009.02111.x] [PMID] [PMCID]
32. Dannenberg H, Speel EJ, Zhao J, Saremaslani P, van der Harst E, Roth J, et al. Chromosomal losses in pheochromocytomas. Am J Pathol. 2000;157(2):353-359. [DOI:10.1016/S0002-9440(10)64547-6] [PMID] [PMCID]
33. Guzy RD, Sharma B, Bell E, Chandel NS, Schumacker PT. SdhB loss triggers tumorigenesis. Mol Cell Biol. 2008;28(2):718-731. [DOI:10.1128/MCB.01338-07] [PMID] [PMCID]
34. Yankovskaya V, Horsefield R, Törnroth S, Luna-Chavez C, Miyoshi H, Léger C, et al. Architecture of succinate dehydrogenase. Science. 2003;299(5607):700-704. [DOI:10.1126/science.1079605] [PMID]
35. Ishii T, Yasuda K, Akatsuka A, Hino O, Hartman PS, Ishii N. SDHC mutation and tumorigenesis. Cancer Res. 2005;65(1):203-209. [DOI:10.1158/0008-5472.203.65.1] [PMID]
36. Owens KM, Aykin-Burns N, Dayal D, Coleman MC, Domann FE, Spitz DR. SDHD mutation and genomic instability. Free Radic Biol Med. 2012;52(1):160-166. [DOI:10.1016/j.freeradbiomed.2011.10.441] [PMID] [PMCID]
37. Slane BG, Aykin-Burns N, Smith BJ, Kalen AL, Goswami PC, Domann FE, et al. SDHC mutation and oxidative stress. Cancer Res. 2006;66(15):7615-7620. [DOI:10.1158/0008-5472.CAN-06-0833] [PMID]
38. Flavahan WA, Drier Y, Johnstone SE, Hemming ML, Tarjan DR, Hegazi E, et al. Chromosomal topology in SDH-deficient GISTs. Nature. 2019;575(7781):229-233. [DOI:10.1038/s41586-019-1668-3] [PMID] [PMCID]
39. Wyvekens N, Valtcheva N, Mischo A, Helmchen B, Hermanns T, Choschzick M, et al. FH-deficient renal cell carcinoma. Genes Chromosomes Cancer. 2020;59(11):611-624. [DOI:10.1002/gcc.22879] [PMID] [PMCID]
40. Tomlinson IP, Alam NA, Rowan AJ, Barclay E, Jaeger EE, Kelsell D, et al. Germline FH mutations. Nat Genet. 2002;30(4):406-410. [DOI:10.1038/ng849] [PMID]
41. Castro-Vega LJ, Buffet A, De Cubas AA, Cascón A, Menara M, Khalifa E, et al. FH mutations and paragangliomas. Hum Mol Genet. 2014;23(9):2440-2446. [DOI:10.1093/hmg/ddt639] [PMID]
42. Clark GR, Sciacovelli M, Gaude E, Walsh DM, Kirby G, Simpson MA, et al. FH mutations and pheochromocytoma. J Clin Endocrinol Metab. 2014;99(10):E2046-E2050. [DOI:10.1210/jc.2014-1659] [PMID]
43. Alam NA, Rowan AJ, Wortham NC, Pollard PJ, Mitchell M, Tyrer J, et al. FH mutations in leiomyomatosis. Hum Mol Genet. 2003;12(11):1241-1252. [DOI:10.1093/hmg/ddg138] [PMID]
44. Toro JR, Nickerson ML, Wei MH, Warren MB, Glenn GM, Turner ML, et al. FH mutations in North America. Am J Hum Genet. 2003;73(1):95-106. [DOI:10.1086/376435] [PMID] [PMCID]
45. Picaud S, Kavanagh KL, Yue WW, Lee WH, Muller-Knapp S, Gileadi O, et al. Structural basis of FH deficiency. J Inherit Metab Dis. 2011;34(3):671-676. [DOI:10.1007/s10545-011-9294-8] [PMID] [PMCID]
46. Estévez M, Skarda J, Spencer J, Banaszak L, Weaver TM. Human fumarase mutation. Protein Sci. 2002;11(6):1552-1557. [DOI:10.1110/ps.0201502] [PMID] [PMCID]
47. Casey RT, McLean MA, Challis BG, McVeigh TP, Warren AY, Mendil L, et al. Fumarate metabolic signature. Clin Cancer Res. 2020;26(2):391-399. [DOI:10.1158/1078-0432.CCR-19-0877] [PMID] [PMCID]
48. Richter S, Gieldon L, Pang Y, Peitzsch M, Huynh T, Letón R, et al. Metabolome-guided genomics. Genet Med. 2019;21(3):705-717. [DOI:10.1038/s41436-018-0106-5] [PMID] [PMCID]
49. Buelow B, Cohen J, Nagymanyoki Z, Frizzell N, Joseph NM, McCalmont T, et al. 2SC and FH immunohistochemistry. Am J Surg Pathol. 2016;40(7):982-988. [DOI:10.1097/PAS.0000000000000625] [PMID]
50. Chen YB, Brannon AR, Toubaji A, Dudas ME, Won HH, Al-Ahmadie HA, et al. HLRCC-associated renal cancer. Am J Surg Pathol. 2014;38(5):627-637. [DOI:10.1097/PAS.0000000000000168] [PMID]
51. Joseph NM, Solomon DA, Frizzell N, Rabban JT, Zaloudek C, Garg K. FH aberrations in uterine leiomyomas. Am J Surg Pathol. 2015;39(11):1529-1539. [DOI:10.1097/PAS.0000000000000504] [PMID] [PMCID]
52. Trpkov K, Hes O, Agaimy A, Bonert M, Martinek P, Magi-Galluzzi C, et al. FH-deficient renal cell carcinoma. Am J Surg Pathol. 2016;40(7):865-875. [DOI:10.1097/PAS.0000000000000626] [PMID]
53. Carter CS, Skala SL, Chinnaiyan AM, McHugh JB, Siddiqui J, Cao X, et al. FH and SDH in cutaneous leiomyomas. Am J Surg Pathol. 2017;41(6):801-809. [DOI:10.1097/PAS.0000000000000822] [PMID]
54. Heinonen HR, Mehine M, Mäkinen N, Pasanen A, Pitkänen E, Karhu A, et al. Metabolomic profiling of uterine leiomyomas. Br J Cancer. 2017;117(12):1855-1864. [DOI:10.1038/bjc.2017.331] [PMID] [PMCID]
55. Zheng L, MacKenzie ED, Karim SA, Hedley A, Blyth K, Kalna G, et al. ASL reversal in FH-deficient cancer. Cancer Metab. 2013;1(1):12. [DOI:10.1186/2049-3002-1-12] [PMID] [PMCID]
56. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, et al. Genomic analysis of glioblastoma. Science. 2008;321(5897):1807-1812. [DOI:10.1126/science.1164382] [PMID]
57. Borger DR, Goyal L, Yau T, Poon RT, Ancukiewicz M, Deshpande V, et al. Circulating 2-hydroxyglutarate. Clin Cancer Res. 2014;20(7):1884-1890. [DOI:10.1158/1078-0432.CCR-13-2649] [PMID] [PMCID]
58. Delahousse J, Verlingue L, Broutin S, Legoupil C, Touat M, Doucet L, et al. D-2HG as surrogate marker. Eur J Cancer. 2018;90:83-91. [DOI:10.1016/j.ejca.2017.11.027] [PMID]
59. Lombardi G, Corona G, Bellu L, Puppa AD, Pambuku A, Fiduccia P, et al. Plasma and urinary 2HG. Oncologist. 2015;20(5):562-570. [DOI:10.1634/theoncologist.2014-0266] [PMID] [PMCID]
60. Natsumeda M, Igarashi H, Nomura T, Ogura R, Tsukamoto Y, Kobayashi T, et al. 2HG accumulation and survival. Acta Neuropathol Commun. 2014;2:158. [DOI:10.1186/s40478-014-0158-y] [PMID] [PMCID]
61. Sim HW, Nejad R, Zhang W, Nassiri F, Mason W, Aldape KD, et al. Tissue 2HG as biomarker. Clin Cancer Res. 2019;25(11):3366-3373. [DOI:10.1158/1078-0432.CCR-18-3205] [PMID]
62. Winter H, Kaisaki PJ, Harvey J, Giacopuzzi E, Ferla MP, Pentony MM, et al. Circulating biomarkers in cholangiocarcinoma. Cancers (Basel). 2019;11(12):1895. [DOI:10.3390/cancers11121895] [PMID] [PMCID]
63. Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, von Deimling A. IDH1 codon 132 mutation. Acta Neuropathol. 2008;116(6):597-602. [DOI:10.1007/s00401-008-0455-2] [PMID]
64. Kang MR, Kim MS, Oh JE, Kim YR, Song SY, Seo SI, et al. IDH1 mutations in cancers. Int J Cancer. 2009;125(2):353-355. [DOI:10.1002/ijc.24379] [PMID]
65. Mardis ER, Ding L, Dooling DJ, Larson DE, McLellan MD, Chen K, et al. AML genome sequencing. N Engl J Med. 2009;361(11):1058-1066. [DOI:10.1056/NEJMoa0903840] [PMID] [PMCID]
66. Borger DR, Tanabe KK, Fan KC, Lopez HU, Fantin VR, Straley KS, et al. IDH mutations in cholangiocarcinoma. Oncologist. 2012;17(1):72-79. [DOI:10.1634/theoncologist.2011-0386] [PMID] [PMCID]
67. Amary MF, Bacsi K, Maggiani F, Damato S, Halai D, Berisha F, et al. IDH mutations in chondrosarcoma. J Pathol. 2011;224(3):334-343. [DOI:10.1002/path.2913] [PMID]
68. Chiang S, Weigelt B, Wen HC, Pareja F, Raghavendra A, Martelotto LG, et al. IDH2 mutations in breast cancer. Cancer Res. 2016;76(24):7118-7129. [DOI:10.1158/0008-5472.CAN-16-0298] [PMID] [PMCID]
69. Fathi AT, Sadrzadeh H, Comander AH, Higgins MJ, Bardia A, Perry A, et al. IDH1 mutation in breast cancer. Oncologist. 2014;19(6):602-607. [DOI:10.1634/theoncologist.2013-0417] [PMID] [PMCID]
70. Minemura H, Takagi K, Sato A, Yamaguchi M, Hayashi C, Miki Y, et al. IDH isoforms in breast carcinoma. Breast Cancer. 2021;28(4):915-926. [DOI:10.1007/s12282-021-01228-x] [PMID]
71. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, et al. IDH mutations in gliomas. N Engl J Med. 2009;360(8):765-773. [DOI:10.1056/NEJMoa0808710] [PMID]
72. Wang HY, Tang K, Liang TY, Zhang WZ, Li JY, Wang W, et al. IDH1 vs IDH2 in gliomas. J Exp Clin Cancer Res. 2016;35:86. [DOI:10.1186/s13046-016-0362-7] [PMID] [PMCID]
73. Shen Y, Zhu YM, Fan X, Shi JY, Wang QR, Yan XJ, et al. AML mutation patterns. Blood. 2011;118(20):5593-5603. [DOI:10.1182/blood-2011-03-343988] [PMID]
74. Choi C, Ganji SK, DeBerardinis RJ, Hatanpaa KJ, Rakheja D, Kovacs Z, et al. 2HG detection by MRS. Nat Med. 2012;18(4):624-629. [DOI:10.1038/nm.2682] [PMID]
75. Gross S, Cairns RA, Minden MD, Driggers EM, Bittinger MA, Jang HG, et al. 2HG in AML. J Exp Med. 2010;207(2):339-344. [DOI:10.1084/jem.20092506] [PMID]
76. Lin AP, Abbas S, Kim SW, Ortega M, Bouamar H, Escobedo Y, et al. D2HGDH regulation. Nat Commun. 2015;6:7768. [DOI:10.1038/ncomms8768] [PMID] [PMCID]
77. Jin G, Reitman ZJ, Duncan CG, Spasojevic I, Gooden DM, Rasheed BA, et al. Wild-type IDH1 disruption. Cancer Res. 2013;73(2):496-501. [DOI:10.1158/0008-5472.CAN-12-2852] [PMID] [PMCID]
78. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. WHO CNS tumor classification. Acta Neuropathol. 2016;131(6):803-820. [DOI:10.1007/s00401-016-1545-1] [PMID]
79. Bleeker FE, Atai NA, Lamba S, Jonker A, Rijkeboer D, Bosch KS, et al. Prognostic IDH1 mutation. Acta Neuropathol. 2010;119(4):487-494. [DOI:10.1007/s00401-010-0645-6] [PMID] [PMCID]
80. Hartmann C, Hentschel B, Wick W, Capper D, Felsberg J, Simon M, et al. Prognosis in anaplastic astrocytomas. Acta Neuropathol. 2010;120(6):707-718. [DOI:10.1007/s00401-010-0781-z] [PMID]
81. Sanson M, Marie Y, Paris S, Idbaih A, Laffaire J, Ducray F, et al. IDH1 mutation as prognostic biomarker. J Clin Oncol. 2009;27(25):4150-4154. [DOI:10.1200/JCO.2009.21.9832] [PMID]
82. Wang F, Zheng Z, Guan J, Qi D, Zhou S, Shen X, et al. Prognostic gene panel for glioblastoma. EBioMedicine. 2018;37:68-77. [DOI:10.1016/j.ebiom.2018.10.031] [PMID] [PMCID]
83. DiNardo CD, Propert KJ, Loren AW, Paietta E, Sun Z, Levine RL, et al. Serum 2HG predicts IDH mutations. Blood. 2013;121(24):4917-4924. [DOI:10.1182/blood-2013-03-493197] [PMID] [PMCID]
84. Miller A, Tong AW, Sweetman L, Theiss A, Murtaza M, Daoud Y, et al. AML with elevated D-2HG. Blood. 2017;130(Suppl 1).
85. Balss J, Thiede C, Bochtler T, Okun J, Saadati M, Benner A, et al. Pretreatment D-2HG levels in AML. Leukemia. 2016;30(4):782-788. [DOI:10.1038/leu.2015.327] [PMID] [PMCID]
86. Brunner AM, Neuberg DS, Wander SA, Sadrzadeh H, Ballen KK, Amrein PC, et al. IDH mutations and chemotherapy response. Cancer. 2019;125(4):541-549. [DOI:10.1002/cncr.31810] [PMID]
87. Andronesi OC, Kim GS, Gerstner E, Batchelor T, Tzika AA, Fantin VR, et al. 2HG detection by spectral-editing MRS. Sci Transl Med. 2012;4(116):116ra4. [DOI:10.1126/scitranslmed.3002693] [PMID] [PMCID]
88. Branzoli F, Di Stefano AL, Capelle L, Ottolenghi C, Valabrègue R, Deelchand DK, et al. IDH status by MRS. Neuro Oncol. 2018;20(7):907-916. [DOI:10.1093/neuonc/nox233] [PMID] [PMCID]
89. Choi C, Raisanen JM, Ganji SK, Zhang S, McNeil SS, An Z, et al. Longitudinal 2HG MRS. J Clin Oncol. 2016;34(33):4030-4039. [DOI:10.1200/JCO.2016.67.1222] [PMID]
90. Esmaeili M, Vettukattil R, Bathen TF. 2HG as MR biomarker. Transl Oncol. 2013;6(2):92-98. [DOI:10.1593/tlo.12280] [PMID] [PMCID]
91. Tietze A, Choi C, Mickey B, Maher EA, Ulhøi BP, Sangill R, et al. Noninvasive IDH assessment. J Neurosurg. 2018;128(2):391-399. [DOI:10.3171/2016.10.JNS161793] [PMID]
92. Radoul M, Hong D, Gillespie AM, Najac C, Viswanath P, Pieper RO, et al. Metabolic biomarkers of mutant IDH inhibition. Metabolites. 2021;11(2):109. [DOI:10.3390/metabo11020109] [PMID] [PMCID]
93. Ballester LY, Lu G, Zorofchian S, Vantaku V, Putluri V, Yan Y, et al. CSF metabolomics in CNS tumors. Acta Neuropathol Commun. 2018;6(1):85. [DOI:10.1186/s40478-018-0588-z] [PMID] [PMCID]
94. Kalinina J, Ahn J, Devi NS, Wang L, Li Y, Olson JJ, et al. D-2HG in CSF. Clin Cancer Res. 2016;22(24):6256-6265. [DOI:10.1158/1078-0432.CCR-15-2965] [PMID] [PMCID]
95. Cuccarini V, Antelmi L, Pollo B, Paterra R, Calatozzolo C, Nigri A, et al. In vivo 2HG MRS. Neurol Sci. 2020;41(2):347-355. [DOI:10.1007/s10072-019-04087-9] [PMID]
96. Fathi AT, Nahed BV, Wander SA, Iafrate AJ, Borger DR, Hu R, et al. Urinary 2HG in glioma. Oncologist. 2016;21(2):214-219. [DOI:10.1634/theoncologist.2015-0342] [PMID] [PMCID]
97. Belykh E, Shaffer KV, Lin C, Byvaltsev VA, Preul MC, Chen L. Blood-brain barrier and neurosurgery. Front Oncol. 2020;10:739. [DOI:10.3389/fonc.2020.00739] [PMID] [PMCID]
98. Nduom EK, Yang C, Merrill MJ, Zhuang Z, Lonser RR. Blood-brain barrier in tumors. J Neurosurg. 2013;119(2):427-433. [DOI:10.3171/2013.3.JNS122226] [PMID] [PMCID]
99. Engqvist MKM, Eßer C, Maier A, Lercher MJ, Maurino VG. Mitochondrial 2HG metabolism. Mitochondrion. 2014;19:275-281. [DOI:10.1016/j.mito.2014.02.003] [PMID]
100. Fan J, Teng X, Liu L, Mattaini KR, Looper RE, Vander Heiden MG, et al. PHGDH produces D-2HG. ACS Chem Biol. 2015;10(2):510-516. [DOI:10.1021/cb500683c] [PMID] [PMCID]
101. Mishra P, Tang W, Putluri V, Dorsey TH, Jin F, Wang F, et al. ADHFE1 as breast cancer oncogene. J Clin Invest. 2018;128(1):323-340. [DOI:10.1172/JCI93815] [PMID] [PMCID]
102. Struys EA, Verhoeven NM, Brunengraber H, Jakobs C. D-2HG formation in lymphoblasts. FEBS Lett. 2004;557(1-3):115-120. [DOI:10.1016/S0014-5793(03)01459-5] [PMID]
103. Xu T, Stewart KM, Wang X, Liu K, Xie M, Ryu JK, et al. Metabolic control of TH17/Treg balance. Nature. 2017;548(7666):228-233. [DOI:10.1038/nature23475] [PMID] [PMCID]
104. Michelucci A, Cordes T, Ghelfi J, Pailot A, Reiling N, Goldmann O, et al. IRG1 and itaconic acid. Proc Natl Acad Sci U S A. 2013;110(19):7820-7825. [DOI:10.1073/pnas.1218599110] [PMID] [PMCID]
105. Schuster EM, Epple MW, Glaser KM, Mihlan M, Lucht K, Zimmermann JA, et al. TFEB-induced itaconate synthesis. Nat Metab. 2022;4(7):856-871. [DOI:10.1038/s42255-022-00605-w] [PMID] [PMCID]
106. Weiss JM, Davies LC, Karwan M, Ileva L, Ozaki MK, Cheng RY, et al. Itaconic acid in tumor crosstalk. J Clin Invest. 2018;128(9):3794-3805. [DOI:10.1172/JCI99169] [PMID] [PMCID]
107. Chen LL, Morcelle C, Cheng ZL, Chen X, Xu Y, Gao Y, et al. Itaconate inhibits TET enzymes. Nat Cell Biol. 2022;24(3):353-363. [DOI:10.1038/s41556-022-00853-8] [PMID] [PMCID]
108. Chen YJ, Li GN, Li XJ, Wei LX, Fu MJ, Cheng ZL, et al. Targeting IRG1 enhances immunotherapy. Sci Adv. 2023;9(17):eadg0654. [DOI:10.1126/sciadv.adg0654] [PMID] [PMCID]
109. Lampropoulou V, Sergushichev A, Bambouskova M, Nair S, Vincent EE, Loginicheva E, et al. Itaconate and inflammation. Cell Metab. 2016;24(1):158-166. [DOI:10.1016/j.cmet.2016.06.004] [PMID] [PMCID]
110. Zhao H, Teng D, Yang L, Xu X, Chen J, Jiang T, et al. Myeloid-derived itaconate. Nat Metab. 2022;4(12):1660-1674. [DOI:10.1038/s42255-022-00676-9] [PMID] [PMCID]
111. Mills EL, Ryan DG, Prag HA, Dikovskaya D, Menon D, Zaslona Z, et al. Itaconate activates Nrf2. Nature. 2018;556(7699):113-117. [DOI:10.1038/nature25986] [PMID] [PMCID]
112. Zhang Z, Chen C, Yang F, Zeng YX, Sun P, Liu P, et al. Itaconate and antibacterial immunity. Mol Cell. 2022;82(15):2844-2857.e10. [DOI:10.1016/j.molcel.2022.06.025] [PMID]
113. Hooftman A, Angiari S, Hester S, Corcoran SE, Runtsch MC, Ling C, et al. Itaconate inhibits inflammasome. Cell Metab. 2020;32(3):468-478.e7. [DOI:10.1016/j.cmet.2020.07.016] [PMID] [PMCID]
114. Swain A, Bambouskova M, Kim H, Andhey PS, Duncan D, Auclair K, et al. Itaconate derivatives and interferon regulation. Nat Metab. 2020;2(7):594-602. [DOI:10.1038/s42255-020-0210-0] [PMID] [PMCID]
115. Dolšak A, Gobec S, Sova M. IDO and TDO as therapeutic targets. Pharmacol Ther. 2021;221:107746. [DOI:10.1016/j.pharmthera.2020.107746] [PMID] [PMCID]
116. Marszalek-Grabska M, Walczak K, Gawel K, Wicha-Komsta K, Wnorowska S, Wnorowski A, et al. Kynurenine metabolism. Pharmacol Ther. 2021;225:107845. [DOI:10.1016/j.pharmthera.2021.107845] [PMID] [PMCID]
117. Du L, Xing Z, Tao B, Li T, Yang D, Li W, et al. IDO1/TDO in glioma malignancy. Signal Transduct Target Ther. 2020;5(1):10. doi:10.1038/s41392-020-0119-2
118. Xiang Z, Li J, Song S, Wang J, Cai W, Hu W, et al. IDO1 metabolite feedback in gastric cancer. J Exp Clin Cancer Res. 2019;38(1):314. [DOI:10.1186/s13046-019-1318-5] [PMID] [PMCID]
119. Bishnupuri KS, Alvarado DM, Khouri AN, Shabsovich M, Chen B, Dieckgraefe BK, et al. Kynurenine activates PI3K-Akt. Cancer Res. 2019;79(6):1138-1150. [DOI:10.1158/0008-5472.CAN-18-0668] [PMID] [PMCID]
120. Wu PY, Yu IS, Lin YC, Chang YT, Chen CC, Lin KH, et al. AhR activation by kynurenine. Cancer Res. 2019;79(21):5550-5562. [DOI:10.1158/0008-5472.CAN-18-3272] [PMID]
121. Venkateswaran N, Lafita-Navarro MC, Hao YH, Kilgore JA, Perez-Castro L, Braverman J, et al. MYC and kynurenine pathway. Genes Dev. 2019;33(17-18):1236-1251. [DOI:10.1101/gad.327056.119] [PMID] [PMCID]
122. Lee R, Li J, Li J, Wu CJ, Jiang S, Hsu WH, et al. Synthetic essentiality of TDO2. Cancer Discov. 2022;12(7):1702-1717. [DOI:10.1158/2159-8290.CD-21-0680] [PMID] [PMCID]
123. Fiore A, Zeitler L, Russier M, Groß A, Hiller MK, Parker JL, et al. Kynurenine import via SLC7A11. Mol Cell. 2022;82(5):920-932.e7. [DOI:10.1016/j.molcel.2022.01.017] [PMID]
124. Liu Y, Liang X, Dong W, Fang Y, Lv J, Zhang T, et al. Kynurenine transfer induces PD-1. Cancer Cell. 2018;33(3):480-494.e7. [DOI:10.1016/j.ccell.2018.02.005] [PMID]
125. Galán-Díez M, Borot F, Ali AM, Zhao J, Gil-Iturbe E, Shan X, et al. Kynurenine and AML. Cancer Discov. 2022;12(4):1106-1123. [DOI:10.1158/2159-8290.CD-21-0692] [PMID] [PMCID]
126. Zhang D, Ning J, Ramprasath T, Yu C, Zheng X, Song P, et al. Kynurenine and heart regeneration. Nat Commun. 2022;13:6371. [DOI:10.1038/s41467-022-33734-7] [PMID]
127. Takenaka MC, Gabriely G, Rothhammer V, Mascanfroni ID, Wheeler MA, Chao CC, et al. AHR/CD39 in glioblastoma. Nat Neurosci. 2019;22(5):729-740. [DOI:10.1038/s41593-019-0370-y] [PMID]
128. Siska PJ, Jiao J, Matos C, Singer K, Berger RS, Dettmer K, et al. Kynurenine and T cell metabolism. EBioMedicine. 2021;74:103742. [DOI:10.1016/j.ebiom.2021.103742] [PMID] [PMCID]
129. Casas-Benito A, Martínez-Herrero S, Martínez A. Succinate-directed cancer therapy. Cancers (Basel). 2023;15(10):2862. [DOI:10.3390/cancers15102862] [PMID] [PMCID]
130. Tretter L, Patocs A, Chinopoulos C. Succinate in tumorigenesis. Biochim Biophys Acta Bioenerg. 2016;1857(8):1086-1101. [DOI:10.1016/j.bbabio.2016.03.012] [PMID]
131. Yang JX, Chuang YC, Tseng JC, Liu YL, Lai CY, Lee AYL, et al. PDLIM2 and mitochondrial ROS. J Exp Clin Cancer Res. 2024;43:169. [DOI:10.1186/s13046-024-03094-9] [PMID] [PMCID]
132. Ježek J, Cooper KF, Strich R. ROS and mitochondrial dynamics. Antioxidants (Basel). 2018;7(1):13. [DOI:10.3390/antiox7010013] [PMID] [PMCID]
133. Hao J, Huang Z, Zhang S, Song K, Wang J, Gao C, et al. Roles of 2-hydroxyglutarate in cancer. Pharmacol Res. 2024;209:107437. [DOI:10.1016/j.phrs.2024.107437] [PMID]
134. Peng S, Chen H, Chen L, Yang G, Liu J, Cheng X, et al. Beyond IDH mutations. Chem Res Toxicol. 2022;35(2):115-124. [DOI:10.1021/acs.chemrestox.1c00254] [PMID]
135. Sullivan LB, Martinez-Garcia E, Nguyen H, Mullen AR, Dufour E, Sudarshan S, et al. Fumarate binds glutathione. Mol Cell. 2013;51(2):236-248. [DOI:10.1016/j.molcel.2013.05.003] [PMID]
136. Zheng L, Cardaci S, Jerby L, MacKenzie ED, Sciacovelli M, Johnson TI, et al. Fumarate-induced senescence. Nat Commun. 2015;6:6001. [DOI:10.1038/ncomms7001] [PMID] [PMCID]
137. Darzi M, Shokrollahi-Barough M, Nazeri E, Majidzadeh-AK, Esmaeili R. Gene co-expression in liposarcoma. Mol Biol Res Commun. 2025;14(3):203-214. doi:10.22099/mbrc.2025.48562.1765
138. Negrini S, Gorgoulis VG, Halazonetis TD. Genomic instability hallmark. Nat Rev Mol Cell Biol. 2010;11(3):220-228. [DOI:10.1038/nrm2858] [PMID]
139. Pandey SN, Afzal M, Uikey J, Ganesan S, Mishra S, Bansal P, et al. ATM and p53 in aging and cancer. Biogerontology. 2025;26(3):102-116. [DOI:10.1007/s10522-025-10249-4] [PMID]
140. Sulkowski PL, Sundaram RK, Oeck S, Corso CD, Liu Y, Noorbakhsh S, et al. Krebs-cycle-deficient syndromes. Nat Genet. 2018;50(8):1086-1092. [DOI:10.1038/s41588-018-0170-4] [PMID] [PMCID]
141. Sulkowski PL, Oeck S, Dow J, Economos NG, Mirfakhraie L, Liu Y, et al. Oncometabolites suppress DNA repair. Nature. 2020;582(7813):586-591. [DOI:10.1038/s41586-020-2363-0] [PMID] [PMCID]
142. Drews RM, Hernando B, Tarabichi M, Haase K, Lesluyes T, Smith PS, et al. Pan-cancer chromosomal instability. Nature. 2022;606(7916):976-983. [DOI:10.1038/s41586-022-04789-9] [PMID] [PMCID]
143. Rahme GJ, Javed NM, Puorro KL, Xin S, Hovestadt V, Johnstone SE, et al. Epigenetic lesions in gliomas. Cell. 2023;186(17):3674-3689.e14. [DOI:10.1016/j.cell.2023.07.023] [PMID] [PMCID]
144. Losman JA, Koivunen P, Kaelin WG Jr. 2-oxoglutarate-dependent dioxygenases. Nat Rev Cancer. 2020;20(12):710-726. [DOI:10.1038/s41568-020-00303-3] [PMID]
145. Gueble SE, Bindra RS. Oncometabolites and DNA damage response. Semin Radiat Oncol. 2022;32(3):206-216. [DOI:10.1016/j.semradonc.2021.09.004] [PMID]
146. Sarkar S, Chang CI, Jean J, Wu MJ. TCA cycle-derived oncometabolites and immunity. J Biomed Sci. 2025;32(1):87. [DOI:10.1186/s12929-025-01186-y] [PMID] [PMCID]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
